Exclusive Summary

• Backed by US-FDA GMP certification and an approved US IND, ensuring top-tier quality systems that significantly mitigate local registration and compliance risks for overseas partners.
• Proven international registration track record with submission dossiers currently under review in Saudi Arabia, South Korea, and Pakistan, providing ready-to-use, high-quality CTD formats to accelerate market entry.
• Perfectly timed to capitalize on the originator's expiring patents and the ongoing global shortage of GLP-1 drugs, serving as a premium alternative in the multi-billion-dollar diabetes and obesity markets.
• Combines world-class regulatory compliance with China's manufacturing cost efficiencies, offering distributors substantial pricing flexibility and high profit margins to conquer both public tenders and out-of-pocket weight-loss markets.